Latest News

Intraperitoneal rintatolimod may boost outcomes with immunotherapies such as pembrolizumab in ovarian cancer.

Robert Coleman, MD, discusses how relacorilant plus nab‑paclitaxel boosts survival in platinum‑resistant ovarian cancer.

Interim data from the LEGEND pivotal cohort show detalimogene achieved complete responses in more than half of patients with BCG-unresponsive non-muscle invasive bladder cancer.

First-in-class double-loaded patient-derived immunotherapy joins pancreatic cancer and glioblastoma in FDA Fast Track portfolio; phase 1/2 trial now recruiting.

Final PRIMO phase 2 data show oral duvelisib drives strong responses in relapsed PTCL, standout AITL benefit, with manageable safety signals.

Shagufta Shaheen, MD, discusses treatment strategies for pancreatic NETs.

Thomas LeBlanc, MD, reviews second-line options for lower-risk MDS after luspatercept failure, highlighting imetelstat’s efficacy, safety, and NCCN-aligned role.

During a live event, Patrick Hagen, MD, evaluated the safety profile of the MajesTEC-3 regimen and considered the impact of early use of teclistamab in multiple myeloma.

CLOVER-WaM data meet FDA-requested threshold; confirmatory trial planned for fourth quarter 2026.

Joshua Sabari, MD, discusses lurbinectedin maintenance candidacy, supportive care strategies, and the critical need for biomarkers in ES-SCLC.

Pelareorep plus FOLFIRI and bevacizumab showed durable responses in second-line RAS-mutant MSS metastatic colorectal cancer.

Cilta-cel achieved complete, sustained responses without induction therapy in the precursor disease to multiple myeloma.

Rashmi Chugh, MD, discusses the outcomes and goals of a promising study for ozekibart plus chemotherapy in patients with relapsed Ewing sarcoma.

VIKTORIA-1 shows gedatolisib plus fulvestrant, with or without palbociclib, boosts PFS after CDK4/6 therapy in PIK3CA-mutant breast cancer.

Jakafi XR offers bioequivalent alternative to twice-daily formulation; pharmacy availability expected by May 8.

Community oncology teams partner with health systems to deliver advanced therapies safely, using hybrid dosing, toxicity backup, and local follow-up.

From pancreatic cancer breakthroughs to pivotal FDA votes, this week’s oncology news highlights progress, setbacks, and shifting regulatory momentum.

The FDA has authorized expanded access to the RAS inhibitor daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma.

The second-generation T-cell immunotherapy Orca-Q demonstrated encouraging outcomes in an ongoing phase 1 trial.

The FDA has approved the first PROTAC in any indication, supported by phase 3 VERITAC-2 data.

S-HIFU achieved 71% ADT-free survival at 30 months in recurrent prostate cancer post-radiation, with better outcomes in patients with lower PSA and Gleason scores.

Phase 3 FLASH2 ends early after interim analysis shows synthetic hypericin photodynamic therapy fails to improve CTCL outcomes, prompting deeper data review and regulator talks.

How community oncology prepares for CAR T and gene therapy: safety gains, tech, payer shifts, and 3 must-have capabilities to expand access.

Explore the April 2026 FDA oncology roundup: full approval for brexu-cel in MCL, priority reviews for I-DXd and zanidatamab, and key lung cancer NDA news.

Expert insights from Shagufta Shaheen, MD, on sequencing PRRT, everolimus, and cabozantinib after SSA progression in advanced GI NETs, balancing PFS gains and tolerability.

The FDA's Oncologic Drugs Advisory Committee voted in favor 7 to 1 that benefits of capivasertib outweighed risks.

During a live event, Ronan J. Kelly, MD, MBA, and participants discussed key considerations for biomarker testing in upper GI cancers.

Mark Stein, MD, explores managing mHSPC through PSMA PET imaging, tumor burden assessment, and AMPLITUDE trial data while considering clinical context.

The FDA's ODAC voted 6-3 against camizestrant for HR+/HER2– breast cancer, citing concerns over the SERENA-6 trial design and a lack of overall survival data.

Clinicians discuss using KEAP1/STK11 mutations to guide CTLA-4 therapy escalation in NSCLC, aiming to overcome PD-1 resistance and improve 5-year survival goals.

The oral gamma secretase inhibitor varegacestat improved progression-free survival and overall response rate vs placebo; full results to be presented at ASCO.